Peripheral Nerve Injury and CGRP Receptor Antagonist Modulate RCP-1 Expression in Primary Sensory Neurons and in Neurons of the Spinal Cord

Abstract

Listen

Translate article

Calcitonin gene-related peptide (CGRP) receptors appear to be rather unique among G-protein receptor superfamily since they may require accessory proteins to be functional. For example, a CGRP receptor clone behaves as a CGRP1 receptor subtype in presence of the RAMP-1 accessory protein but as an adrenomedullin receptor when coexpressed with RAMP-2. Another putative protein bearing no sequence homology to the RAMPs has been cloned and named CGRP receptor component or RCP. This protein is involved in the signal transduction pathway of the CGRP receptors. Previously, using highly specific RCP-1 antibody, we immunocytochemically demonstrated the localization of RCP-1 immunoreactivity in the brain and peripheral nervous system of the rat. The aim of this study was to determine if RCP-1 expression in primary sensory neurons and spinal motoneurons could be modulated by partial sciatic nerve injury, a model for neuropathic pain, or by intrathecal administration of CGRP8-37, a CGRP receptor antagonist. We found that partial sciatic nerve injury reduced RCP-1 expression in neurons of both dorsal and ventral horns of the lumbar spinal cord. Interestingly, following intrathecal daily injection of CGRP8-37 (4 µg/day for 7 days), RCP-1 immunoreactive axons and neurons were significantly increased in both dorsal and ventral horns of the rat lumbar spinal cord. These data suggest that RCP-1 expression in the primary sensory neurons and spinal motoneurons is subject to modulation by peripheral nerve injury as well as CGRP receptor activation. It could be used as a reliable marker to represent CGRP receptor. Supported by grant from CIHR.